Risk stratification and medical therapy of pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Respir J
Autors principals: Galiè, Nazzareno, Channick, Richard N., Frantz, Robert P., Grünig, Ekkehard, Jing, Zhi Cheng, Moiseeva, Olga, Preston, Ioana R., Pulido, Tomas, Safdar, Zeenat, Tamura, Yuichi, McLaughlin, Vallerie V.
Format: Artigo
Idioma:Inglês
Publicat: European Respiratory Society 2019
Matèries:
Series
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6351343/
https://ncbi.nlm.nih.gov/pubmed/30545971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01889-2018
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars